BAX - Baxter International Inc.

NYSE - NYSE Delayed Price. Currency in USD
73.33
-0.84 (-1.13%)
At close: 4:00PM EDT

73.33 0.00 (0.00%)
After hours: 4:20PM EDT

Stock chart is not supported by your current browser
Previous Close74.17
Open74.12
Bid70.00 x 39400
Ask76.00 x 800
Day's Range73.28 - 74.35
52 Week Range58.81 - 75.62
Volume2,362,981
Avg. Volume3,085,998
Market Cap39.267B
Beta1.06
PE Ratio (TTM)48.95
EPS (TTM)1.50
Earnings DateJul 26, 2018
Forward Dividend & Yield0.76 (1.02%)
Ex-Dividend Date2018-05-31
1y Target Est78.21
Trade prices are not sourced from all markets
  • Baxter CEO on what's driving his company's stock price to...
    CNBC Videos6 days ago

    Baxter CEO on what's driving his company's stock price to...

    Baxter CEO Jose Almeida discusses future M&A, new product launches, and gearing up for hurricane season with CNBC's Meg Tirrell.

  • BSX or BAX: Which is a Better Pick for Your Portfolio Now?
    Zacks9 hours ago

    BSX or BAX: Which is a Better Pick for Your Portfolio Now?

    After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).

  • Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
    Zacks2 days ago

    Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

    Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

  • Boston Scientific’s Valuations and Price Performance
    Market Realist5 days ago

    Boston Scientific’s Valuations and Price Performance

    Boston Scientific’s (BSX) enterprise value is $45.1 billion, and its enterprise-value-to-revenue ratio is 4.98x. The stock is trading at a forward PE multiple of 21.86x, which is expected to have a five-year growth multiple of 2.13x. Its price-to-sales ratio is 5.23x, and its price-to-book ratio is 6.72x. Its enterprise-value-to-EBITDA ratio is 18.5x.

  • Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?
    Zacks7 days ago

    Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?

    Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.

  • Baxter International’s Financial Performance
    Market Realist12 days ago

    Baxter International’s Financial Performance

    Baxter International (BAX) generated net sales of $2.7 billion in the first quarter of 2018 compared to $2.5 billion in Q1 2017. Baxter’s gross margins were affected by a negative impact from foreign exchange rates and the impact of lost sales due to Hurricane Maria and incremental supply chain costs in the first quarter. The company’s gross profit increased marginally from $1 billion in Q1 2017 to $1.1 billion in Q1 2018.

  • Analyzing Baxter International’s Stock Repurchases and Cash Flows
    Market Realist12 days ago

    Analyzing Baxter International’s Stock Repurchases and Cash Flows

    Baxter International (BAX) has been regularly carrying out stock repurchases, a positive sign for investors. Baxter International generated $447 million from operating activities in the first quarter of 2018 compared to $206 million in Q1 2017. Baxter’s days payable outstanding increased from 48.6 days in Q1 2017 to 57.8 days in Q1 2018.

  • Baxter International’s Global Business Units in Q1 2018
    Market Realist12 days ago

    Baxter International’s Global Business Units in Q1 2018

    Baxter International’s (BAX) global business units include the following: Renal Care: peritoneal dialysis and hemodialysis therapies Medication Delivery: intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices Pharmaceuticals: premixed and oncology drug platforms, inhaled anesthesia, critical care products, and pharmacy compounding services Nutrition: parenteral nutrition therapies Advanced Surgery: biological products, medical devices used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention Acute Therapies and Other: continuous ...

  • A Close Look at Baxter International’s Acquisitions
    Market Realist12 days ago

    A Close Look at Baxter International’s Acquisitions

    Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018 on the back of higher demand for Baxter’s CRRT (continuous renal replacement therapies) systems. In July 2017, Baxter International acquired Claris Lifesciences’ subsidiary Claris Injectables for a cash consideration of $629 million. Through this acquisition, Baxter gained capabilities in the production of essential generic injectable medicines such as anesthesia and analgesics, renal, anti-infectives, and critical care in bags, vials, and ampoules.

  • Analyzing Baxter International’s Geographic Segments
    Market Realist12 days ago

    Analyzing Baxter International’s Geographic Segments

    Baxter generates a major part of its revenues from the Americas segment, which contributed $1.44 billion to the company’s total revenues in the first quarter, from $1.37 billion in Q1 2017. The company generated $724 million of revenue from its EMEA segment in the first quarter of 2018 compared to $631 million in the first quarter of 2017.

  • How Much Upside Do Analysts See in Baxter Stock?
    Market Realist12 days ago

    How Much Upside Do Analysts See in Baxter Stock?

    Baxter International (BAX) provides a broad portfolio of essential healthcare products. Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating. Six have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.3 with a target price of $78.33, implying an upside potential of 4.1% over the stock’s closing price of $75.28 on June 5.

  • Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates
    Zacks12 days ago

    Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates

    Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.

  • See what the IHS Markit Score report has to say about Baxter International Inc.
    Markit12 days ago

    See what the IHS Markit Score report has to say about Baxter International Inc.

    Baxter International Inc NYSE:BAX

  • ACCESSWIRE15 days ago

    Akers Biosciences and Three Additional Stocks Under Scanner in the Medical Supplies Space

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on AKER sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Medical Instruments & Supplies equities: Akers Biosciences Inc. (NASDAQ: AKER), Antares Pharma Inc. (NASDAQ: ATRS), Baxter International Inc. (NYSE: BAX), and Becton, Dickinson and Co. (NYSE: BDX).

  • Forbes16 days ago

    You May Be Losing Money By Not Redlining Language Changes In 10-Ks

    The HBS finance paper Lazy Prices shows that this rich information is hidden in 10-Ks and investors are missing it (or at least taking their time incorporating it into stock prices). Changes to the language and construction of financial reports also have strong implications for firms’ future returns: a portfolio that shorts “changers” and buys “non-changers” earns up to 188 basis points in monthly alphas (over 22% per year) in the future. Changes in language referring to the executive (CEO and CFO) team, regarding litigation, or in the risk factor section of the documents are especially informative for future returns.

  • The Zacks Analyst Blog Highlights: Facebook, Intel, Boeing, Las Vegas Sands and Baxter
    Zacks16 days ago

    The Zacks Analyst Blog Highlights: Facebook, Intel, Boeing, Las Vegas Sands and Baxter

    The Zacks Analyst Blog Highlights: Facebook, Intel, Boeing, Las Vegas Sands and Baxter

  • Here's Why You Should Invest in Baxter International Now
    Zacks20 days ago

    Here's Why You Should Invest in Baxter International Now

    Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.

  • Business Wire21 days ago

    Baxter Supported Nine New Abstract Presentations at the 55th ERA-EDTA Congress That Further Demonstrate Value of HDx Therapy Enabled by THERANOVA

    Baxter International Inc. (BAX), a global innovator in renal care, announced new data reinforcing that expanded hemodialysis (HDx) enabled by the THERANOVA dialyzer clears large middle molecules at a higher rate when compared to standard hemodialysis (HD), and equivalent or higher removal rates compared to high-volume hemodiafiltration (HDF). Two studies presented also found that albumin levels remained stable during HDx treatment. The findings were shared during scientific exchange at the 55th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), May 24-27.

  • 5 Stocks Near 52-Week High With Potential to Scale Higher
    Zacks21 days ago

    5 Stocks Near 52-Week High With Potential to Scale Higher

    Here are some stocks trading near their 52-week high levels and still with plenty of room for upside.

  • US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch
    Zacks21 days ago

    US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch

    Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market

  • Intuitive Surgical Commences Direct Operations in India
    Zacks21 days ago

    Intuitive Surgical Commences Direct Operations in India

    Intuitive Surgical (ISRG) looks to install a broader base of its flagship da Vinci surgical system through distributor Vattikuti in India.

  • Business Wire21 days ago

    Baxter Unveiled Updates to SHARESOURCE Remote Patient Management Platform for Home Dialysis Patients at ERA-EDTA 2018

    Baxter International Inc. , a global innovator in renal care, announced the availability of two program updates for its SHARESOURCE remote patient management platform to support greater accessibility and efficiencies in remotely viewing patient data.

  • Baxter International Stock Is at an All-Time High: Is It a Buy?
    Motley Fool21 days ago

    Baxter International Stock Is at an All-Time High: Is It a Buy?

    Can the momentum continue for this hot healthcare stock?

  • TheStreet.com22 days ago

    Medical Device Stocks Could Be Gearing Up to Be Market Leaders

    Medical devices is another industry that Jim Cramer believes will hold up better in this current environment of volatile energy prices and interest rates. Let's take a look at five companies in this space, Baxter International Inc. The chart and indicators of Baxter International show underlying strength and could outperform the averages in the days and weeks ahead.

  • Trade War May Pull MedTech Down: 3 Stocks to Defy the Odds
    Zacks22 days ago

    Trade War May Pull MedTech Down: 3 Stocks to Defy the Odds

    The medical device lobby is extremely apprehensive on proposed tariffs on Chinese products as these could significantly affect international trade.